TransmedicsTMDX
TMDX
About: TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Employees: 584
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
49% more repeat investments, than reductions
Existing positions increased: 124 | Existing positions reduced: 83
0.15% more ownership
Funds ownership: 108.82% [Q3] → 108.97% (+0.15%) [Q4]
17% less call options, than puts
Call options by funds: $51.5M | Put options by funds: $62.4M
18% less funds holding
Funds holding: 365 [Q3] → 298 (-67) [Q4]
45% less first-time investments, than exits
New positions opened: 66 | Existing positions closed: 119
60% less capital invested
Capital invested by funds: $5.68B [Q3] → $2.28B (-$3.4B) [Q4]
100% less funds holding in top 10
Funds holding in top 10: 9 [Q3] → 0 (-9) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$75
4%
upside
Avg. target
$103
42%
upside
High target
$125
74%
upside
4 analyst ratings
3 positive
75%
1 neutral
25%
0 negative
0%
JP Morgan Allen Gong 44% 1-year accuracy 4 / 9 met price target | 4%upside $75 | Neutral Downgraded | 17 Dec 2024 |
Piper Sandler Matt O'Brien 64% 1-year accuracy 35 / 55 met price target | 25%upside $90 | Overweight Maintained | 11 Dec 2024 |
Baird Joe Vruwink 49% 1-year accuracy 20 / 41 met price target | 67%upside $120 | Outperform Maintained | 11 Dec 2024 |
Oppenheimer Suraj Kalia 67% 1-year accuracy 16 / 24 met price target | 74%upside $125 | Outperform Maintained | 3 Dec 2024 |
Financial journalist opinion
Based on 159 articles about TMDX published over the past 30 days
Neutral
Accesswire
14 hours ago
Shareholders of TransMedics Group, Inc. Should Contact Levi & Korsinsky Before April 15, 2025 to Discuss Your Rights - TMDX
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your TransMedics Group, Inc. (NASDAQ:TMDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/transmedics-group-inc-lawsuit-submission-form-2?prid=131432&wire=1 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
14 hours ago
Lowey Dannenberg Notifies TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ: TMDX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ: TMDX) for violations of the federal securities laws on behalf of investors who purchased or acquired TransMedics common stock between February 28, 2023 and January 10, 2025, inclusive (the “Class Period”).
Neutral
Business Wire
16 hours ago
TMDX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that TransMedics Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK--(BUSINESS WIRE)---- $TMDX #ClassAction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against TransMedics Group, Inc. (“TransMedics” or “the Company”) (NASDAQ: TMDX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Tr.
Neutral
Accesswire
16 hours ago
Levi & Korsinsky Notifies Shareholders of TransMedics Group, Inc.(TMDX) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your TransMedics Group, Inc. (NASDAQ:TMDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/transmedics-group-inc-lawsuit-submission-form-2?prid=131408&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
16 hours ago
TMDX SECURITIES NEWS: TransMedics Group has been Sued for Securities Fraud - Investors are Alerted to Contact BFA Law by April 15 Legal Deadline (NASDAQ:TMDX)
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ:TMDX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in TransMedics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/transmedics-group-inc.
Neutral
Accesswire
18 hours ago
Investors who Lost Money on TransMedics Group, Inc. (TMDX) Should Contact Levi & Korsinsky About Pending Class Action - TMDX
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your TransMedics Group, Inc. (NASDAQ:TMDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/transmedics-group-inc-lawsuit-submission-form-2?prid=131388&wire=1 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
18 hours ago
TRANSMEDICS INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that TransMedics Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TMDX
SAN DIEGO, Feb. 21, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of TransMedics Group, Inc. (NASDAQ: TMDX) publicly traded securities between February 28, 2023 and January 10, 2025, inclusive (the “Class Period”), have until April 15, 2025 to seek appointment as lead plaintiff of the TransMedics class action lawsuit. Captioned Jewik v. TransMedics Group, Inc., No. 25-cv-10385 (D. Mass.), the TransMedics class action lawsuit charges TransMedics as well as certain of TransMedics' top executives with violations of the Securities Exchange Act of 1934.
Neutral
Accesswire
19 hours ago
April 15, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against TMDX
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your TransMedics Group, Inc. (NASDAQ:TMDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/transmedics-group-inc-lawsuit-submission-form-2?prid=131372&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
20 hours ago
Investors in TransMedics Group, Inc. Should Contact Levi & Korsinsky Before April 15, 2025 to Discuss Your Rights - TMDX
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your TransMedics Group, Inc. (NASDAQ:TMDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/transmedics-group-inc-lawsuit-submission-form-2?prid=131341&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
21 hours ago
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against TransMedics Group, Inc.
LOS ANGELES, CA / ACCESS Newswire / February 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 3, 2022, and February 3, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before April 15, 2025.
Charts implemented using Lightweight Charts™